Evid Based Nurs 11:52 doi:10.1136/ebn.11.2.52
  • Treatment

Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years

I Ford

Dr I Ford, University of Glasgow, Glasgow, UK;


In middle-aged men with hypercholesterolaemia and no history of myocardial infarction (MI), does 5 years of treatment with pravastatin have long-term benefits for prevention of coronary heart disease (CHD)?



post-trial follow-up of a randomised, placebo-controlled trial (West of Scotland Coronary Prevention Study [WOSCOPS]).


unclear allocation concealment.


blinded during the trial period {clinicians, patients, data collectors, and outcome adjudication committees}.*

Follow-up period:

original trial follow-up was 5 years; this study followed up surviving patients (96%) for 10 more years.


{coronary screening clinics in the UK}.*


6595 men {45–64 years of age}* (mean age 55 y) with no history of MI and low-density lipoprotein cholesterol concentrations ⩾155 mg/dl (4.01 mmol/l) on 2 occasions.


pravastatin, 40 …

No Related Web Pages

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article